US EditionThe Pill War Heats Up: Novo Relies On Wegovy To Reclaim Leadership From Eli Lilly
2 Articles
2 Articles
Novo Nordisk vs. Lilly: The pill war intensifies in the US obesity market. Oral Wigobi surpasses 300,000 prescriptions in the two months following launch. Stock price falls 50% over the past year; will Novo Nordisk seize a chance for a turnaround? Lilly also developing oral obesity drug Opoglyfron; approval expected in April. The weight loss drug launched by Danish pharmaceutical company Novo Nordisk
The Pill War Heats Up: Novo Relies On Wegovy To Reclaim Leadership From Eli Lilly
The Wegovy pill from Novo Nordisk is providing the Danish pharmaceutical company with an opportunity to regain its market share from Eli Lilly. This latest entrant into the booming global weight-loss drug market has already launched at a faster pace than almost any previous pharmaceutical product.The once-daily Wegovy pill received approval from U.S. regulators in late December. By the end of February, American doctors had issued more than 300,0…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
